Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.

Apoptosis : an international journal on programmed cell death - 1 Jun 2009

Gasparian Marine E, Chernyak Boris V, Dolgikh Dmitry A, Yagolovich Anne V, Popova Ekaterina N, Sycheva Anna M, Moshkovskii Sergey A, Kirpichnikov Mikhail P

Abstract excerpt

TRAIL (tumor necrosis factor (TNF) related apoptosis-inducing ligand) has been introduced as an extrinsic pathway inducer of apoptosis that does not have the toxicities of Fas and TNF. However, the therapeutic potential of TRAIL is limited because of many primary tumor cells are resistant to TRAIL. Despite intensive investigations, little is known in regards to the mechanisms underlying TRAIL selectivity and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochalasin D
Share to Mutant Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Paclitaxel

Share to Proto-Oncogene Proteins c-bcl-2

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to Surface Plasmon Resonance

Share to TNF-Related Apoptosis-Inducing Ligand

Share to Ultracentrifugation

Source

Identifiers

PMID: 19412666
DOI: 10.1007/s10495-009-0349-3

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.PMID 19412666Read ↗

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.Semantic proximity Read ↗

DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.Semantic proximity Read ↗

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Semantic proximity Read ↗

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.Semantic proximity Read ↗

Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding.Semantic proximity Read ↗

The effect of cisplatin on cytotoxicity of anticancer cytokine TRAIL and its receptor-selective mutant variant DR5-B1.Semantic proximity Read ↗

State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAILSemantic proximity Read ↗

Directed Change in TNFα Specificity to Create DR5 Antagonists.Semantic proximity Read ↗

Therapeutic applications of TRAIL receptor agonists in cancer and beyondSemantic proximity Read ↗

TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.Semantic proximity Read ↗

Death receptors as targets for anti‐cancer therapySemantic proximity Read ↗

Generation of a novel TRAIL mutant by proline to arginine substitution based on codon bias and its antitumor effects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.